BioFire Diagnostics
BioFire Diagnostics, now part of bioMérieux, specializes in syndromic infectious disease testing using multiplex PCR technology. Their mission is to improve public health worldwide by providing fast, accurate, and comprehensive diagnostic solutions that support antimicrobial stewardship, enhance patient care, and reduce healthcare costs. The company emphasizes the importance of rapid syndromic testing in combating healthcare-associated infections (HAIs) and respiratory illnesses, especially during peak respiratory seasons and the COVID-19 pandemic.
Industries
Nr. of Employees
Very Large (1000+)
BioFire Diagnostics
The company’s physical address is not specified in the provided content.
Patents
Products
Respiratory multiplex PCR panel (≈22-target, ~45 min)
A syndromic respiratory nucleic-acid amplification panel that detects common viral and bacterial respiratory pathogens with reported sensitivity and specificity and an approximate run time of 45 minutes.
Blood culture identification multiplex PCR panel (~1 hour from positive culture)
A blood-culture identification panel that detects gram-positive, gram-negative, yeast targets and multiple antimicrobial resistance gene markers from positive blood cultures with rapid turnaround to guide antimicrobial therapy.
Gastrointestinal multiplex PCR panel (~1 hour)
A GI syndromic panel that detects a broad set of gastrointestinal bacterial, viral, and parasitic pathogens and reports results rapidly to reduce additional diagnostic procedures.
Meningitis/encephalitis multiplex PCR panel
A CNS syndromic panel for rapid detection of bacterial and viral causes of meningitis/encephalitis to enable earlier clinical decision-making, with reported reductions in time-to-diagnosis compared with traditional workflows.
Joint infection multiplex PCR panel (synovial fluid, ~0.2 mL)
A multiplex nucleic-acid test for synovial fluid capable of detecting bacterial and yeast targets plus antimicrobial resistance genes using a small sample volume and providing results in about one hour.
Point-of-care low-plex respiratory PCR system (5- or 15-target, ~15 min)
A point-of-care PCR platform optimized for outpatient settings offering targeted and expanded respiratory panels with some configurations cleared for CLIA-waived use and results in approximately 15 minutes.
Respiratory multiplex PCR panel (≈22-target, ~45 min)
A syndromic respiratory nucleic-acid amplification panel that detects common viral and bacterial respiratory pathogens with reported sensitivity and specificity and an approximate run time of 45 minutes.
Blood culture identification multiplex PCR panel (~1 hour from positive culture)
A blood-culture identification panel that detects gram-positive, gram-negative, yeast targets and multiple antimicrobial resistance gene markers from positive blood cultures with rapid turnaround to guide antimicrobial therapy.
Gastrointestinal multiplex PCR panel (~1 hour)
A GI syndromic panel that detects a broad set of gastrointestinal bacterial, viral, and parasitic pathogens and reports results rapidly to reduce additional diagnostic procedures.
Meningitis/encephalitis multiplex PCR panel
A CNS syndromic panel for rapid detection of bacterial and viral causes of meningitis/encephalitis to enable earlier clinical decision-making, with reported reductions in time-to-diagnosis compared with traditional workflows.
Joint infection multiplex PCR panel (synovial fluid, ~0.2 mL)
A multiplex nucleic-acid test for synovial fluid capable of detecting bacterial and yeast targets plus antimicrobial resistance genes using a small sample volume and providing results in about one hour.
Point-of-care low-plex respiratory PCR system (5- or 15-target, ~15 min)
A point-of-care PCR platform optimized for outpatient settings offering targeted and expanded respiratory panels with some configurations cleared for CLIA-waived use and results in approximately 15 minutes.
Services
Phone and email-based technical support and customer assistance for instrument and assay use, plus access to documentation and troubleshooting resources.
Educational resources and training materials aimed at laboratorians and clinicians to support correct use and interpretation of multiplex molecular diagnostic tests.
Program support for external researchers conducting clinical studies using the diagnostic platforms or assays.
Onsite or remote demonstrations and trial evaluations to inform purchase and implementation decisions.
Online articles and guidance for the general public and clinicians about prevention measures (vaccination, hand hygiene, masking, distancing, isolation) and when to seek testing.
Phone and email-based technical support and customer assistance for instrument and assay use, plus access to documentation and troubleshooting resources.
Educational resources and training materials aimed at laboratorians and clinicians to support correct use and interpretation of multiplex molecular diagnostic tests.
Program support for external researchers conducting clinical studies using the diagnostic platforms or assays.
Onsite or remote demonstrations and trial evaluations to inform purchase and implementation decisions.
Online articles and guidance for the general public and clinicians about prevention measures (vaccination, hand hygiene, masking, distancing, isolation) and when to seek testing.
Expertise Areas
- Syndromic infectious disease diagnostics
- Rapid molecular diagnostics for respiratory, bloodstream, gastrointestinal, CNS, pneumonia, and joint infections
- Point-of-care PCR testing and CLIA-waived workflows
- Integration of diagnostics with antimicrobial stewardship programs
Key Technologies
- Multiplex PCR (multiplex nucleic-acid amplification)
- Disposable pouch/cartridge-based automated PCR
- Point-of-care low-plex rapid PCR systems (short runtime)
- High-throughput laboratory PCR systems
News & Updates
BioFire Diagnostics emphasizes the importance of rapid syndromic testing in reducing HAIs and improving patient outcomes, especially during respiratory season and the COVID-19 pandemic.
BioFire Diagnostics emphasizes the importance of rapid syndromic testing in reducing HAIs and improving patient outcomes, especially during respiratory season and the COVID-19 pandemic.